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Ectopic Expression of Zmiz1 Induces Cutaneous
Squamous Cell Malignancies in a Mouse Model
of Cancer
Laura M. Rogers1, Jesse D. Riordan1, Brian L. Swick2, David K. Meyerholz3 and Adam J. Dupuy1
Cutaneous squamous cell carcinoma (SCC) is the second most common form of cancer in the human population,
yet the underlying genetic mechanisms contributing to the disease are not well understood. We recently
identified Zmiz1 as a candidate oncogene in nonmelanoma skin cancer through a transposon mutagenesis
screen. Here we show that transposon-induced mutations in Zmiz1 drive expression of a truncated transcript that
is similar to an alternative endogenous ZMIZ1 transcript found to be overexpressed in human SCCs relative to
normal skin. We also describe an original mouse model of invasive keratoacanthoma driven by skin-specific
expression of the truncated Zmiz1 transcript. Unlike most mouse models, Zmiz1-induced skin tumors develop
rapidly and in the absence of promoting agents such as phorbol esters. In addition, we found that the alternative
Zmiz1 isoform has greater protein stability than its full-length counterpart. Finally, we provide evidence that
ZMIZ1 is overexpressed in a significant percentage of human breast, ovarian, and colon cancers in addition
to human SCCs, suggesting that ZMIZ1 may play a broader role in epithelial cancers.
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INTRODUCTION
Nonmelanoma skin cancer is the most common human cancer
worldwide with B1 million new cases reported in the United
States annually (Alam and Ratner, 2001). Although basal cell
carcinoma is more common than squamous cell carcinoma
(SCC), SCC is a more aggressive disease and metastasizes at low
frequency (Alam and Ratner, 2001). Current treatments rely upon
surgical excision of the cancerous tissue. However, surgical
removal can be disfiguring as tumors develop on sun-exposed
skin. The major risk factor for developing nonmelanoma skin
cancer is UV exposure, and UV-induced TP53 mutations are
frequently observed in both basal cell carcinoma and SCC (Brash
et al., 1991; Benjamin and Ananthaswamy, 2007). In addition,
46% of human SCCs have mutations in HRAS, many of which
are also UV induced (Pierceall et al., 1991). Despite knowledge
of these prevalent mutations, targeted therapies are not in
widespread use and greater understanding of the genetics
contributing to this disease will aid in their design.
We recently performed a Sleeping Beauty (SB) transposon
mutagenesis screen in mice in which a variety of epithelial
tumor types were produced, the most common being
cutaneous malignancies formerly designated as SCCs (Dupuy
et al., 2009). Nearly 90% of cutaneous tumors harbored
transposon insertions within the Zmiz1 locus, likely resulting
in overexpression of an N-terminally truncated protein (i.e.,
Zmiz1D1-185). Interestingly, Zmiz1 has previously been
implicated in lymphoma through retroviral mutagenesis
screens (Sauvageau et al., 2008; Uren et al., 2008).
The ZMIZ1 locus encodes a protein with a PAT domain, an
MSX-interacting zinc-finger (MIZ) domain, and a putative
nuclear localization sequence. The molecular function of
ZMIZ1 is not well characterized, but the MIZ domain is
predicted to function as an E3 SUMO (Small Ubiquitin-like
Modifier) ligase with homology to the PIAS (protein inhibitor
of activated Stats) family. Prior work demonstrated that ZMIZ1
increases transcriptional activity of the androgen receptor,
p53, and Smad3/4 when overexpressed in cultured cells
(Sharma et al., 2003; Li et al., 2006; Lee et al., 2007). The
increased androgen receptor activity was associated with
sumoylation of androgen receptor, apparently mediated by
ZMIZ1 (Sharma et al., 2003). A constitutive Zmiz1 knockout
mouse allele has been described, but homozygous deletion of
Zmiz1 causes early embryonic lethality, thus preventing the
study of Zmiz1 function in adult tissues (Beliakoff et al., 2008).
Consequently, current knowledge regarding Zmiz1 function is
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inadequate to explain how its overexpression might lead
to skin cancer.
Here we report the results of experiments performed to
validate Zmiz1 as an oncogene and to explore how Zmiz1
truncation by transposon insertion might confer selective
advantage to tumor cells. We found that overexpression of
Zmiz1D1-185 in mouse skin was sufficient to induce tumors,
thereby creating a transgenic model of cutaneous malignancy.
Interestingly, we discovered that a similar endogenous isoform
is expressed in a tumor-specific manner in human skin.
We also observed nuclear accumulation of ZMIZ1 in human
breast, ovarian, and colon cancers, supporting a widespread
relevance of our mouse model to other epithelial cancers, and
not only SCCs.
RESULTS
Tumor-specific expression of an alternative ZMIZ1 transcript
We recently identified Zmiz1 as a cancer gene important for
the induction of cutaneous SCC using SB transposon mutagen-
esis (Dupuy et al., 2009). Significantly, all insertions
were located within intron 8, and oriented in such a way as
to promote expression of a truncated transcript including
exons 9–24 (Figure 1a). Importantly, the SB-induced transcript
strongly resembles an endogenous human ZMIZ1 isoform
(uc001kag.2), which includes an alternative promoter and
exon that is spliced into exon 7 of the full-length transcript
(Figure 1a).
Transcriptome and chromatin immunoprecipitation data
generated by the ENCODE Project from a variety of cell lines
are consistent with the presence of an alternative promoter just
upstream of the alternative exon (Birney et al., 2007)
(Supplementary Figure S1 online). Expression of the short
isoform (i.e., ZMIZ1short) is likely regulated by the activity of
this alternative promoter. All known and predicted functional
domains are preserved in the predicted open reading frame of
this short isoform (Figure 1b).
We detected endogenous expression of ZMIZ1short in MCF7
breast cancer cells; however, the expression was not detected
in the other human cell lines tested, including immortalized
normal keratinocyte cell lines HaCaT and N-HSK-1
(Figure 1c). ZMIZ1short transcript was also measured in
human SCCs and, when possible, matched normal skin
samples. Interestingly, we observed tumor-specific ZMIZ1short
upregulation in four of six samples by quantitative real-time
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Figure 1. Tumor-specific expression of ZMIZ1short. (a) Diagram of the ZMIZ1 locus in mouse and human. The human alternative (Alt.) promoter is located
in intron 6 and drives expression of the ZMIZ1short transcript. This transcript is similar to the transcript produced by Sleeping Beauty (SB) transposon insertion
into mouse intron 8. (b) The amino-acid sequence of human and mouse short forms differs by B60 amino acids at the N-termini, but are otherwise nearly
identical. Note that both full-length and ZMIZ1short contain all currently annotated functional protein domains. (c) Reverse-transcriptase–PCR (RT–PCR) analysis
confirmed that ZMIZ1short is expressed in MCF7, but not in the other human cell lines tested. (d) Quantitative RT–PCR performed on human squamous cell
carcinomas (SCCs) shows increased tumor-specific expression of ZMIZ1short. Dotted lines indicate the average Ct values for normal skin.
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reverse-transcriptase–PCR (qRT–PCR; Figure 1d). The full-
length transcript (i.e., ZMIZ1) was upregulated in only two
of six samples.
Zmiz1D1-185 expression in mouse skin induces squamous cell
tumors
As previously mentioned, we predicted that transposon-
induced expression of the Zmiz1D1-185 is oncogenic. To test
this hypothesis, we engineered transgenic mice that condi-
tionally express Zmiz1D1-185 (Figure 2a). A lox-stop-lox strat-
egy was employed to prevent ubiquitous expression of
Zmiz1D1-185. Cre-mediated recombination will delete the
DsRed reporter embedded in the lox-stop-lox cassette and
induce expression of the downstream Zmiz1D1-185-IRES-EGFP
cassette. Two Zmiz1D1-185 founder animals showed
detectable levels of the DsRed reporter in the skin and
were used to establish transgenic lines 207-Zmiz1D1-185 and
163-Zmiz1D1-185.
Each line was crossed to keratin 14 (K14)-Cre transgenic
mice to induce expression of Zmiz1D1-185 in the proliferative
basal layer of the cutaneous epidermis (Dassule et al., 2000).
Transgene expression in normal adult skin was assessed by
western blot analysis of enhanced green fluorescent protein
(EGFP) expression. As expected, EGFP expression was readily
detectable in double-transgenic skin by western blot, but
undetectable in skin from single-transgenic mice (Figure 2b).
Cre-mediated expression of 163-Zmiz1D1-185 was less effi-
cient, as evidenced by lower EGFP protein levels in double-
transgenic skin (Supplementary Figure S2 online). Given that
both Zmiz1D1-185 transgenes are likely multicopy concate-
mers, the discrepancy in EGFP expression is likely caused by
Cre-mediated deletion of the transgene. Similar situations have
previously been described (Grippo et al., 2002). Nevertheless,
both Zmiz1D1-185 transgenic lines show Cre-inducible
expression.
A cohort of Zmiz1D1-185;K14-Cre double-transgenic mice
(n¼ 54) was generated and aged alongside Zmiz1D1-185
(n¼ 18) or K14-Cre (n¼35) single-transgenic littermate con-
trols (Figure 2c). Over 85% of double-transgenic mice spon-
taneously developed an average of 2.7 skin tumors per mouse
with a mean latency of 14 weeks (Po0.0001). In all cases, the
lesions were variably sized crateriform masses filled with
compact keratin and lined by proliferative stratified squamous
epithelium, a morphology consistent with keratoacanthoma
(KA). Similarly, a more comprehensive study of the SB-
induced tumors from Dupuy et al. (2009) showed identical
histology, and hence these will also be referred to as KAs for
the remainder of this article. Zmiz1D1-185-induced masses
compressed subjacent tissues and exhibited cutaneous
muscle invasion in 23 of 147 tumors (15.6%). Double-
transgenic mice from line 163-Zmiz1D1-185 also developed
KAs, but exhibited lower penetrance with increased latency.
This is likely because of the lower transgene expression levels
observed (Supplementary Figure S2 online). These results are
consistent with the hypothesis that truncated Zmiz1 is an
oncoprotein, and suggest that expression of ZMIZ1short may
also directly contribute to human SCCs.
Gene expression profiling of Zmiz1D1-185-induced skin tumors
The Zmiz1D1-185;K14-Cre double-transgenic mice represent
the first published in vivo validation of Zmiz1 as an oncogene,
but the biological functions of Zmiz1 are not well studied.
Thus, we sought to further characterize the Zmiz1-induced
tumors to determine if any mechanistic insights could be
gained. We generated gene expression profiles from five
independent tumors from 207-Zmiz1D1-185;K14-Cre transgenic
mice along with six normal control skin samples from
207-Zmiz1D1-185;K14-Cre, 207-Zmiz1D1-185, or K14-Cre trans-
genic mice.
Normalized gene expression profiles were compared with
identify genes that showed X2-fold change in expression
between tumor and normal skin with a false discovery rate of
o5%. This identified 701 and 603 genes that were up- or
down-regulated, respectively (Supplementary Table S1
online). Differential expression of six of these genes was
verified using qRT–PCR (Supplementary Figure S3 online).
Analysis of these results using DAVID (Database for Annota-
tion, Visualization, and Integrated Discovery) (Huang da et al.,
2009) or gene set enrichment analysis (Subramanian et al.,
2005) did not reveal any significant conservation among the
differentially regulated genes. Repeating these analyses using
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Figure 2. Zmiz1D1-185 transgenic mice develop skin tumors. (a) Diagram
of the Cre-inducible Zmiz1D1-185 transgene. (b) Western blot showing that skin
from Zmiz1D1-185 single-transgenic mice has nearly undetectable expression
of enhanced green fluorescent protein (EGFP), whereas double-transgenic mice
display detectable EGFP expression. (c) Kaplan–Meier survival curve of
mouse line 207 showing tumor-free survival of keratin 14 (K14)-CreTg/þ ;
Zmiz1D1-185 Tg/þ double-transgenic mice (circles, n¼ 54), K14-Creþ /þ ;
Zmiz1D1-185 Tg/þ single-transgenic MICE (squares, n¼18), and K14-CreTg/þ ;
Zmiz1D1-185 þ /þ single-transgenic mice (triangles, n¼ 35). Double-transgenic
mice developed skin tumors with an average latency of 14 weeks after birth,
whereas single-transgenic controls did not develop skin tumors (log-rank,
Po0.0001). (d) Western blot confirms overexpression of the Zmiz1D1-185
transgenic protein in mouse tumors. Endogenous Zmiz1 expression is
undetectable in normal skin.
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only genes that showed a X5-fold change in expression also
failed to reveal any significant trends.
Zmiz1 accumulates in the nuclei of mouse KAs and human SCCs
Zmiz1 protein expression was evaluated in SB-induced KAs by
immunohistochemical staining of formalin-fixed, paraffin-
embedded skin sections. As predicted, tumors with transposon
insertions in the Zmiz1 locus displayed high levels of
Zmiz1 expression (Figure 3a). Conversely, Zmiz1 protein
was undetectable in normal mouse skin (Figure 3b), although
the endogenous full-length transcript is expressed (Dupuy
et al., 2009). Based on these findings, we conclude that the
majority of Zmiz1 protein detected in SB-induced tumors is
derived from the truncated Zmiz1 transcript.
Similarly, tumor tissue from Zmiz1D1-185;K14-Cre double-
transgenic mice displayed the same strong Zmiz1 nuclear
expression pattern that was observed in spontaneous
SB-induced KAs (Figure 3c). Interestingly, normal adult
double-transgenic skin did not express detectable levels of
Zmiz1 protein by immunohistochemistry or western blot
(Figures 2d and 3d). This led us to hypothesize that Cre-
mediated recombination results in complex transgene rear-
rangements with high frequency and results in a lack of
transgene expression in most cells. Thus, Zmiz1D1-185 over-
expression is a rare event that drives hyperplasia, and
eventually tumorigenesis. If this is true, expression of the
Zmiz1D1-185 transgene should be tumor specific.
DsRed and EGFP RNA expression was measured by
qRT–PCR in normal skin from double- and single-transgenic
mice, as well as in tumors (Supplementary Figure S4 online).
We found that some level of DsRed expression was retained
even after Cre recombination, suggesting that recombination is
inefficient. Furthermore, although transgenic Zmiz1D1-185
expression in normal skin is not detectable at the protein
level, we are able to detect expression of EGFP at the RNA
level. Consistent with our hypothesis, EGFP RNA expression is
greatly increased in tumors. Similarly, a comparison of the
normalized expression values for all probes corresponding to
Zmiz1 exons from our exon array data sets showed tumor-
specific overexpression of exons encoded by the Zmiz1D1-185
transgene. Expression of these exons in normal skin from
Zmiz1D1-185;K14-Cre double-transgenic mice was similar to
that of nontransgenic control skin samples (Supplementary
Figure S4 online).
Our results indicate that Zmiz1D1-185 is an oncogene
involved in skin cancer in mice (Figure 2c). In addition,
ZMIZ1short is overexpressed in human SCCs but not normal
keratinocytes (Figure 1c and d). However, protein expression
in human SCCs has not been assessed. Therefore, we analyzed
a panel of human SCCs by immunohistochemistry to deter-
mine the frequency of ZMIZ1 nuclear accumulation. Consis-
tent with our observations in mouse KAs, 14 of 19 human
SCCs showed nuclear accumulation of ZMIZ1 (Figure 3e and
f). These data, combined with the fact that overexpression of
Zmiz1D1-185 in mouse skin is sufficient to produce skin lesions,
indicate that ZMIZ1 is involved in the etiology of human
SCCs.
Finally, we obtained a tumor tissue array from the National
Cancer Institute to assess ZMIZ1 expression in breast, ovarian,
colon, and lung tumors. In all, 28% of breast, 15% of ovarian,
and 10% of colon cancers displayed strong nuclear ZMIZ1
expression when analyzed by immunohistochemistry (Table 1
and Supplementary Figure S5 online). This result suggests a
conserved role for ZMIZ1 in cancer development across
diverse epithelial tissue types.
Biological impact of Zmiz1 protein truncation
As previously mentioned, transposon insertions in our SB
screen clustered in intron 8 of Zmiz1, demonstrating a strong
preference for a transcript mimicking ZMIZ1short rather than
full-length ZMIZ1. In an attempt to explain why the short-form
might give tumor cells a selective advantage, we examined
steady-state protein expression levels of full-length and
Figure 3. Aberrant nuclear accumulation of Zmiz1 in tumor tissue.
(a) Immunohistochemical analysis (IHC) reveals overexpression of Zmiz1 in
Sleeping Beauty (SB)-induced tumors with transposon insertions in intron 8.
(b) Zmiz1 expression is undetectable by IHC in normal mouse skin.
Bars¼ 50mm. Similarly, nuclear accumulation was observed in keratin 14
(K14)-CreTg/þ ; Zmiz1D1-185 Tg/þ double-transgenic tumors (c), but not normal
skin from double-transgenic mice (d). Bars¼ 100mm. (e) Strong nuclear ZMIZ1
expression was observed in 14 of 19 human cutaneous squamous cell
carcinomas (SCCs) when analyzed by IHC. (f) Example of a human SCC
without ZMIZ1 overexpression. Bars¼ 100mm.
Table 1. Mixed tumor array ZMIZ1 expression data
Tumor type % Nuclear Zmiz1 No. of tumors examined
Breast 28% 32
Ovarian 15% 40
Colon 10% 28
Lung 0% 41
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truncated Zmiz1 expressed from recombinant retroviruses in
multiple cell lines (Figure 4). Higher steady-state expression of
Zmiz1D1-185 was consistently observed across independent
cell lines, despite no significant differences in transcript levels
as assessed by qRT–PCR (data not shown). This suggests that
Zmiz1 protein stability is regulated. Consistent with this
hypothesis, Zmiz1 protein stability was increased upon treat-
ment with the proteasomal inhibitor MG132 (Figure 4). This
result indicates that increased protein stability might confer a
selective advantage to tumor cells expressing Zmiz1D1-185
during tumorigenesis.
DISCUSSION
We previously identified Zmiz1 as a candidate cancer gene in
cutaneous squamous cell malignancies using SB transposon
insertional mutagenesis (Dupuy et al., 2009). The frequency of
ZMIZ1 mutation in human cancer is unknown, and although
ZMIZ1 transcripts have been sequenced in a variety of tumor
types, very few independent tumors have been tested for any
single tumor type (Forbes et al., 2011). However, an
alternative ZMIZ1 promoter has recently been annotated and
is located just upstream of an alternative exon that splices into
exon 7 of the full-length transcript. This endogenous transcript
is predicted to produce an N-terminally truncated protein
(ZMIZ1short) that is strikingly similar to the Zmiz1 truncation
selected by the SB system.
Endogenous ZMIZ1short is expressed in MCF7 breast cancer
cells, but not in two immortalized human keratinocyte cell
lines (HaCat and N-HSK-1). When we assessed ZMIZ1short
expression status in a panel of human SCC samples, we
observed increased tumor-specific expression when compared
with normal skin. Furthermore, expression of the short form in
mouse skin leads to tumor formation with remarkably short
latency, suggesting that Zmiz1D1-185 provides a robust onco-
genic stimulus. Taken together, we conclude that expression
of the short form not only correlates with tumor status in both
human SCCs and mouse models, but also ZMIZ1short expres-
sion may play a causal role in tumor development.
It should be noted that the histology of skin tumors induced
by skin-specific Zmiz1D1-185 expression was consistent with
the diagnosis of KA rather than SCC. KAs can be defined by
their tendency to spontaneously regress. However, it is
debated whether these are early-stage tumors that may
progress into invasive SCCs, or if they remain a distinct class
of squamous hyperplasia (Ko, 2010). Efforts to develop
histological methods to distinguish KAs from SCCs have
failed to provide reliable and specific markers (Karaa and
Khachemoune, 2007; Mandrell and Santa Cruz, 2009).
Regardless, skin-specific Zmiz1D1-185 expression is clearly
capable of producing invasive squamous cell malignancies
that did not spontaneously regress. Whether these would
become even more aggressive upon the acquisition of
additional mutations is unknown.
Until now, the role of Zmiz1 in cutaneous malignancy has
been unappreciated, and our transgenic skin tumor model
may lend unique insight into the biology of nonmelanoma
skin cancer for a variety of reasons. For example, the majority
of genetically engineered mouse models of nonmelanoma skin
cancer require promotion with a phorbol ester such as 12-O-
tetradecanoylphorbol-13-acetate and produce mostly benign
papillomas, only some of which progress to SCC (Vassar et al.,
1992; Wang et al., 1998; Jansen et al., 2001; Liu et al., 2006).
Most of these models have also been constructed on
susceptible inbred strain backgrounds (e.g., FVB/n, BALB/c)
(van Hogerlinden et al., 1999; Proweller et al., 2006; Diez
et al., 2009). Despite these features, many existing mouse
models develop tumors with a long latency. In contrast,
Zmiz1D1-185; K14-Cre transgenic mice rapidly develop
tumors on a resistant strain background without the need
for promotion with 12-O-tetradecanoylphorbol-13-acetate
(Figure 2). Furthermore, we did not detect any spontaneous
mutations in either Hras (n¼14) or Trp53 (n¼13) in
Zmiz1D1-185-induced KAs (Supplementary Figure S6 online),
demonstrating the strong oncogenic potential of Zmiz1. The
status of Zmiz1short expression in mouse models of SCC is
currently unknown, and it may be useful to investigate
whether Zmiz1 also plays a role in these models as KAs are
rarely seen in two-stage chemical carcinogenesis experiments.
In an effort to further characterize our model, gene expres-
sion profiling was performed on transgenic tumors. Many of
the downregulated genes in tumors are involved in muscle
function (e.g., Myh1, Ttn, Acta1). It should be noted that,
unlike normal skin, tumors are largely devoid of hair follicles
and their associated arrector pili muscles. As a consequence,
the decreased expression of muscle genes observed in tumors
could be a result of variation in cellular composition and may
not directly contribute to Zmiz1-induced transformation.
Among the genes showing the greatest increase in expres-
sion in tumor relative to normal skin samples are members of
the small proline-rich protein (Sprr) and serine peptidase
inhibitor (Serpin) families (Supplementary Figure S3 online).
Some of these family members have previously been shown to
be associated with KA and/or SCC (Kato and Torigoe, 1977;
De Heller-Milev et al., 2000). In particular, overexpression of
Serpinb3a has been shown to mediate susceptibility to skin
tumors in mice (Gariboldi et al., 2003). Therefore, these genes
represent likely candidates for elucidating a mechanism by
which Zmiz1 induces tumor formation.
One of the few proposed biological functions of ZMIZ1 is
an E3 SUMO ligase activity (Sharma et al., 2003). A variety
of E3 SUMO ligases have been reported to have roles in
promoting genomic stability and DNA repair (Potts, 2009;
MG132
Zmiz1-HA
Zmiz1Δ1–185-HA
β-Tub
HeLa MCF7 N-HSK-1
– – – – – –+ + + + + +
Figure 4. Zmiz1D1-185 displays increased protein stability. Western blots show
higher steady-state protein expression in Zmiz1D1-185-HA-expressing HeLa,
MCF7, and N-HSK-1 cells than those stably expressing full-length Zmiz1-HA,
despite lacking significant differential transcript expression as analyzed by
quantitative real-time reverse-transcriptase–PCR (qRT–PCR; data not shown).
Where indicated, MG132 (20mM) treatment increased protein stability,
suggesting that Zmiz1 and Zmiz1D1-185 are degraded by the proteasome and
that stability is regulated at the protein level.
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Bartek and Hodny, 2010). We report that Zmiz1D1-185 has
oncogenic function in the skin, but whether its SUMO ligase
activity is required for oncogenesis is currently unknown.
Presumably, both full-length Zmiz1 and Zmiz1D1-185 could
function as E3 SUMO ligases, yet there is clearly selection for
the short form in SB-induced tumors. Our data suggest that
expression of Zmiz1D1-185 could be because of its increased
protein stability. Therefore, expression of Zmiz1D1-185 or
ZMIZ1short would lead to prolonged sumoylation activity,
which may ultimately contribute to the oncogenic potential
of Zmiz1.
Our experimental results include data directly supporting
Zmiz1 as an oncogene, the development and initial charac-
terization of an original mouse model of skin cancer, and the
discovery that an endogenous human alternative ZMIZ1
transcript is expressed in a tumor-specific manner. We also
report that frequent aberrant ZMIZ1 expression occurs in
human SCCs, as well as in a subset of human breast, ovarian,
and colon cancers, demonstrating a potential role in the
development of a variety of human epithelial cancers.
Although ZMIZ1short expression status in these cancers is
unknown, the results of our experiments indicate that ZMIZ1
is causally involved in tumorigenesis. Our data suggest that
further study of the role that ZMIZ1 plays in cancer could have
widespread affect on our current understanding of these
diseases.
MATERIALS AND METHODS
ZMIZ1 and ZMIZ1short qRT–PCR
Total RNA was extracted from the stably transduced cell lines or
human tissues using the PerfectPure RNA Tissue Kit (5-Prime,
Gaithersburg, MD). Total complementary DNA was generated with
the SuperScript III First-Strand Synthesis System (Invitrogen, Carlsbad,
CA) using the oligo dT primer. qPCR was performed using
the Platinum SYBR Green qPCR SuperMix (Invitrogen) with the
following primers: ZMIZ1altexF (50-GCGACCGGTGCAACTTCT
A-30), ZMIZ1ex8R (50-GACAGAGTGGGTTTCATGGAG-30), ZMI-
Z1Ex6F (50-AATCCTGCCAACTTCCACAA-30), ZMIZ1ex7R (50-AGCA
GTCTGTAGCCGAGGTC-30), TBPex2F (50-GCTGAGAAGAGTGTGC
TGGA-30), and TBPex3R (50-GCCATAAGGCATCATTGGAC-30).
ZMIZ1 or ZMIZ1short Ct values were first normalized to TBP Ct
values, and then to N-HSK-1 using the DDCt computational method
(Livak and Schmittgen, 2001). This study was conducted in adherence
to the Declaration of Helsinki Principles. Patients provided written
consent for studies using human tissues and all procedures were
approved by the Institutional Review Board.
Generation of Zmiz1D1-185 transgenic mice
Exons 9–24 of Zmiz1 complementary DNA were PCR amplified from
the National Institutes of Health (NIH) Mammalian Gene Collection
IRAV clone ID 6856060 (Invitrogen) using primers Zmiz1-F
(50-GCTAGCCCTATGGCCAATGCCAACAA-30) and Zmiz1-R (50-AG
ATCTGTTGTTCTCAAAGAGAGACA-30). This fragment was digested
with NheI/BglII and cloned into the NheI/XhoI sites of pTraffic
(Basheer W et al., in preparation) along with a linker to add a
stop codon (annealed Linkerþ (50-GATCCTAAAGATCTC-30) and
Linker (50-TCGAGAGATCTTTAG-30) oligos). This construct was
sent to the University of Iowa Transgenic Animal core facility to
generate Zmiz1D1-185 transgenic mice on a B6SJL F1 background.
Animals used for aging were backcrossed to C57BL/6 for three
generations before breeding to K14-Cre mice (004782, Jackson
Laboratory, Bar Harbor, ME). All aging experiments were performed
following guidelines approved by the University of Iowa Institutional
Animal Care and Use Committee.
Immunohistochemistry
Formalin-fixed, paraffin-embedded skin tumors were cut into 5mm
sections and mounted on glass slides, The ImmPRESS Antibody
Peroxidase Kit was used for immunolabeling (Vector Laboratories,
Burlingame, CA) using anti-RAI17 (AbGent, San Diego, CA) in a 1:50
dilution overnight at 4 1C. Sections were counterstained with Hema-
toxylin QS (Vector Laboratories) and mounted in Permount
(Fisher Scientific, Pittsburgh, PA) for light microscopy. Primary anti-
body incubation was omitted in negative controls.
Generation of stable cell lines and MG132 treatment
MCF7 and HeLa cells were obtained from ATCC (Manassas, VA).
N-HSK-1 keratinocytes were a gift from Aloysius J Klingelhutz
(Gourronc et al., 2010). Retroviral Zmiz1 constructs were produced
by co-transfection of GP2-293 packaging cells with the pVSV-G
packaging plasmid and pQCXIN, or pQCXIN containing Zmiz1 or
Zmiz1D1-185. Retroviral supernatants were collected 24 hours later
and applied to proliferating cells. Stably transduced cells were
selected 24 hours later with media containing 400mg ml 1 (HeLa,
MCF7) or 100mg ml 1 (N-HSK-1) G418. Selection was maintained
for 12 days, whereupon resistant clones were pooled and expanded
in selection media.
Total complementary DNA was generated as previously described.
Ectopic expression of Zmiz1 or Zmiz1D1-185 mRNA in stably trans-
duced cell lines was assessed by qPCR with primers against the
neomycin resistance sequence (Neo forward: 50-TGAATGAACTGC
AGGACGAG-30 and Neo reverse: 50-ATACTTTCTCGGCAGGAGC
A-30). Proteasomal degradation was inhibited by culturing cells in
20mM MG132 (Sigma, St Louis, MO) for 24 hours.
Western blotting
Total protein was collected by lysing with RIPA. Samples were boiled
in a reducing buffer and SDS-PAGE was performed. Protein was
transferred to nitrocellulose membranes for western blotting. Anti-
bodies used were anti-HA (1:5,000, Covance, Princeton, NJ), anti-
RAI17 (1:100, Abgent), and anti-b-Tubulin (1:1,000, Sigma-Aldrich,
St Louis, MO).
See Supplementary Methods online for microarray analysis, trans-
genic mouse qRT-PCR, Hras1 and Trp53 sequencing, and Zmiz1
expression vector generation.
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